β-Adrenergic cocktail

PreclinicalSmall molecule

RRichard Barry Moss

β-Adrenergic cocktail is one of 6 small molecule programs targeting ILD. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

ILDCompleted

ILDPreclinical

Completed

Competition

Competitive Landscape

5 competitors in ILD

#DrugCompanyPhaseTrials

Zometa

Pfizer

Approved

1 2

Romosozumab

Amgen

Phase 3

1 3

Siplizumab

UUniversity of Alabama at Birmingham

Phase 1

1 4

ASP-001

AAspargo Labs, Inc

Phase 1

1 5

β-Adrenergic cocktail

RRichard Barry Moss

Preclinical

1 6

Dehydration

MMode Sensors AS

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

ILD1 trial

(Study: Vertex IIS) Does Ivacaftor Alter Wild Type CFTR-Open Probability In The Sweat Gland Secretory Coil?

Completed·RRichard Barry Moss·N/A·NCT02310789·8 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for β-Adrenergic cocktail. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — β-Adrenergic cocktail compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for β-Adrenergic cocktail. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Richard Barry Moss company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: RRichard Barry Moss

β-Adrenergic cocktail

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

ILD1 trial

References

Drug Info

Quick Facts

Related News